X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: DS-3201
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Oral presentation highlights data from phase 1 study of valemetostat showing promising clinical activity in patients with relapsed/refractory PTCL and ATL. DS-3201 is a potential first-in-class, potent and selective small molecule EZH1/2 dual inhibitor.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
